Bausch+Lomb Results Presentation Deck
2Q22 Financial Highlights & Segment Drivers - Revenue
Total Company Revenue
Millions USD
934
2Q21
941
2Q22
+6%
organic revenue ¹,2 growth
• Driven by strong demand across key
franchises and durable portfolio with high
brand equity
BAUSCH + LOMB
Strong performance notwithstanding FX
headwind of $46M
Vision Care
64%
$589M
36%
Contact Lens ■Consumer
2 Q 22
+11%
• Strong demand for key franchises: Lumify®
(+21% reported revenue growth), Bio True®
Solutions Franchise (+39% reported revenue
growth) and Ocuvite® + PreserVision®
(+7% reported revenue growth)
Opportunity to build out specialty contact lens.
portfolio with new launch of Revive TM; brand
expansion with launch of Bio True® Hydration
Plus Multi-Purpose Solution
ORGANIC
55%
..
.
Surgical
27%
$184M
■ Implantables ■ Equipment
■ Consumables/Other
18%
REVENUE
+7%
Continued market recovery / backlog of
elective surgeries
Demand for consumables (+3% reported
revenue growth; +13% organic revenue
growth ¹.2) and implantables (+4% reported
revenue growth; +10% organic revenue
growth 1.2)
Increase in procedure volume in Western
Europe driving growth in International Surgical
Ophthalmic
Pharmaceuticals
41%
$168M
U.S.
CHANGE
International
59%
1,2
1. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.
2. Organic revenue growth/change, a non-GAAP ratio, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.
3. IQVIA NPA monthly..
(10%)
• U.S. impacted by tail end of LOE products and
generic performance and competition
Vyzulta® saw 36% TRx growth³; Approved in
18 countries, including Lebanon in 2Q22;
Launched in Thailand in 2Q22 and upcoming
launch in Brazil expected in 4Q22
. Submitted NDA for NOV03;
Filing acceptance expected in 3Q22
7View entire presentation